EGFR and non-small cell lung carcinoma: Therefore, to properly addressed this problem, we designed this randomized, phase-2 study comparing the efficacy and tolerability of erlotinib 100 mg/d vs. gefitinib 250 mg/d in patients with EGFR-mutated advanced NSCLC.